Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment
- First Online:
- 1.2k Downloads
An increased production of reactive oxygen species (ROS) could contribute to the development of diabetic nephropathy. NAD(P)H oxidase might be an important source of ROS production in kidney as reported in blood vessels. In this study, we show the increased expression of essential subunits of NAD(P)H oxidase, NOX4 and p22phox, in the kidney of diabetic rats.
The levels of mRNA of both NOX4 and p22phox were evaluated in kidney from streptozotocin-induced diabetic rats and age-matched control rats at 4 and 8 weeks after onset of diabetes by Northern blot analysis. The localization and expression levels of these components and 8-hydroxy-deoxyguanosine (8-OHdG), which is a marker of ROS-induced DNA damage, were also evaluated by immunostaining.
The levels of both NOX4 and p22phox mRNA were increased in the kidney of diabetic rats as compared with control rats. Immunostaining analysis showed that the expression levels of NOX4 and p22phox were clearly increased in both distal tubular cells and glomeruli from diabetic rats. Both the localization and the expression levels of these components were in parallel with those of 8-OHdG. Interventive insulin treatment for 2 weeks completely restored the increased levels of these components in the diabetic kidney to control levels in parallel with those of 8-OHdG.
This study provides evidence that NAD(P)H oxidase subunits, NOX4 and p22phox, were increased in the kidney of diabetic rats. Thus, NAD(P)H-dependent overproduction of ROS could cause renal tissue damage in diabetes. This might contribute to the development of diabetic nephropathy.
KeywordsOxidative stress NAD(P)H oxidase NOX4 p22phox 8-hydroxy-deoxyguanosine nephropathy
reactive oxygen species
- NAD(P)H oxidase
nicotinamide adenine dinucleotide phosphate oxidase
protein kinase C
An increased production of reactive oxygen species (ROS) is supposed to contribute to the development of diabetic vascular complications including nephropathy [1, 2, 3, 4, 5, 6]. However, the source of ROS production remains controversial. It has been postulated that hyperglycaemia could produce ROS through various mechanisms such as enhanced formation of advanced glycation endproducts (AGEs) , altered polyol pathway activity [2, 7] and increased superoxide release from mitochondria . In contrast, accumulating evidence has suggested that NAD(P)H oxidase is the most important source of ROS production in vascular tissues and cells [9, 10, 11, 12]. Recent reports have implicated that this enzyme might be involved in the pathophysiology of vascular diseases including hypercholesterolaemia , atherosclerosis [14, 15, 16], and hypertension . Previously, we showed that high glucose level stimulated ROS production through protein kinase C (PKC)-dependent activation of NAD(P)H oxidase in cultured aortic endothelial cells and smooth muscle cells . This finding suggests that activation of NAD(P)H oxidase could account for an increased production of ROS in diabetes. In consistency with this idea, several reports have recently shown that the activity of NAD(P)H and the levels of its subunit proteins are increased in the aortae from animal models of diabetes [19, 20] and in the saphenous vein and internal mammary artery from diabetic patients with coronary artery disease .
Since the kidney is also known to be an organ susceptible to oxidative damage [22, 23], oxidative stress might play a role in the development of diabetic nephropathy as in other diabetic vascular complications. Although vascular oxidases are similar to the phagocytic NAD(P)H oxidase, they have a unique family of enzymes . The phagocytic NAD(P)H oxidase complex comprises a membrane-associated cytchrome b558 composed of gp91phox (NOX2) and p22phox and several cytosolic regulatory subunits (P47phox, p40phox, p67phox and Rac1 or Rac2). The heme-binding subunit of cytochrome b558 that is essential for enzyme activity is a gp91phox, a glycosylated flavoprotein associated with p22phox. As a homolog of gp91phox in the kidney, NOX4 (Renox) has been cloned recently [25, 26]. It has been implicated that NOX4, as a major source of ROS production in the kidney, could have a role under pathological conditions [25, 26]. We therefore speculated that NOX4 might be involved in development of diabetic nephropathy. The aim of this study is to evaluate the expression of NOX4 and p22phox in kidney from streptozotocin-induced diabetic rats and to relate these changes to oxidative damage to renal tissues.
Methods and materials
Male Wistar rats were bred under pathogen-free conditions at Kyushu University Animal Centre, Fukuoka, Japan. We formed two experimental groups: streptozotocin (STZ)-induced diabetic rats and age-matched control rats. The animals had free access to tap water and standard chow (Clea Japan, Tokyo). At 8 weeks of age, the rats were injected intraperitoneally with STZ (Sigma, St. Louis, Mo., USA) at 80 mg/kg body weight. One day after injection, diabetes was confirmed by the development of hyperglycaemia (>300 mg/dl blood glucose). For interventive insulin treatment, one-half of the diabetic rats were treated with insulin starting at 6 weeks after onset of diabetes. During the next 2 weeks, intermediate-acting insulin (Novolin N; Novo Nordisk, Tokyo, Japan) was subcutaneously administered twice a day. The doses of insulin to be given were determined each time from a sliding scale, according to blood glucose concentrations, to achieve strict glucose control. The study was approved by the committee for Ethics on Animal Experiments, Graduate School of Medical Sciences, Kyushu University and the Guide for Care and Use of Laboratory Animals.
Northern blot analysis
At 4 and 8 weeks after onset of diabetes, rats were anaesthetized by intraperitoneal injection of pentobarbital (80 mg/kg) and killed by bleeding before performance of surgical procedures. The kidney was rapidly excised and separated into cortices and medullae. Then, the samples were frozen in liquid nitrogen and kept at −80°C until use. Total RNA was extracted using Isogen (Waco, Osaka, Japan) from the frozen samples. Of the total RNA, 20 µg was electrophoresed on a 1% agarose gel containing 2.2 mol formaldehyde, and then transferred to a Hybond-N+ nylon membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). After immobilization by UV cross-linking, prehybridization was at 68°C for at least 2 h following the addition of ExpressHyb Hybridization Solution (Clontech, Palo Alto, Calif., USA). The membrane was hybridized with each probe, which was labelled using the Megaprime DNA Labelling System (Amersham Pharmacia Biotech) and (α-32P) dCTP. cDNA probes for rat NOX4 encodes the region that corresponds to amino acids 1–360, and for rat p22phox encodes full length. Unincorporated 32P was removed using Biospin P30 columns (BioRad, Hercules, Calif., USA). The radioactivity corresponding to each band was visualized by a bioimage analyzer, Multi Bio Imager STORM (Amersham Pharmacia Biotech). The densities of individual bands were normalized to 18S ribosomal RNA.
Immunostaining of NOX4 was carried out as described previously . The kidneys were fixed in 10% formaldehyde, and embedded in paraffin. Paraffin sections were cut at 3 µm, and deparaffinized. After inactivation of endogenous peroxidase with 3% H2O2 in methanol for 15 min at room temperature, the sections were pre-incubated for 30 min with 1% bovine serum albumin in phosphate buffered saline (PBS). The samples were subsequently incubated with anti-human NOX4 rabbit polyclonal antibody  (1:1000 dilution) overnight at 4°C, washed in PBS, and probed with anti-rabbit IgG antibody labelled with peroxidase [Histofine Simple Stain MAX PO(R), Nichirei Corp., Tokyo, Japan] for 30 min at room temperature. As a negative control, the primary antibody was replaced with sera obtained from a rabbit before immunization. The sites of peroxidase were visualized with diaminobenzidine (Nichirei Corp.). For p22phox staining, the samples were incubated with anti-human p22phox goat polyclonal antibody (0.2 µg/ml) (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) overnight at 4°C, washed in PBS, and probed with anti-goat IgG antibody labelled with peroxidase [Histofine Simple Stain MAX PO(G)] for 30 min at room temperature. As a negative control, the primary antibody was replaced with normal goat serum. The sections were counterstained with haematoxylin before being examined under a light microscope (Olympus, Tokyo, Japan).
For 8-hydroxy-deoxyguanosine (8-OHdG) staining, the samples were incubated with anti-8-OHdG mouse monoclonal antibody (1 µg/ml) (Japan Institute for the Control of Aging, Fukuroi, Japan) overnight at 4°C, washed in PBS, and probed with anti-mouse IgG antibody labelled with peroxidase [Histofine Simple Stain MAX PO(M)] for 30 min at room temperature, and the sites of peroxidase were visualized with diaminobenzidine. As a negative control, the primary antibody was replaced with mouse IgG.
Human mesangial cells were obtained from Clonetics (East Rutherford, N.J., USA). The cells were maintained in a Mesangial Cell Growth Medium (MsGM) (Clonetics) containing 5% foetal calf serum in an atmosphere of 95% O2/5% CO2 at 37°C. The cells used in these experiments were from 4th to 6th passages. For the experiments, the cells were allowed to reach confluence in 100 mm dishes, and then the medium was changed to an MsGM supplemented with 0.5% serum and high glucose level (400 mg/dl) or normal glucose level (100 mg/dl). Firstly, the effect of high glucose level on ROS production in cultured mesangial cells was examined using electron spin resonance (ESR) spectroscopy as previously described . Briefly, the cells were removed from the dishes by treatment with 0.25% trypsin, centrifuged at 800 g for 5 min, and suspended in the DMEM without serum at a concentration of 1×107 cells/ml. The nitroxide radical, carboxy-TEMPO acetoxymethyl ester (CxT-AM), was added to the cell suspension at the final concentration of 20 mmol/l and the samples were mixed quickly but gently. Then, immediately, the samples were drawn into a gas-permeable Teflon tube (Zeus Industries, Raritan, N.J., USA) and inserted into a quartz ESR tube open at each end. Experiments were carried out at 37°C. ESR spectra were recorded with an ESR spectrometer (JES-RE-1X; JEOL, Akishima, Japan) operating at X-band (9.45 GHz). CxT-AM was hydrolyzed inside the cells, retained in the cytoplasm, and then reduced to the corresponding hydroxylamine, leading to the loss of paramagnetism. The ESR signal intensity decreased gradually after administration and the signal decay curve of CxT-AM was obtained by semi-logarithmically plotting the peak heights of the ESR signals. The curve was almost linear over the first 5 min of decay, allowing the initial velocity as the clearance constant (spin clearance rate). The spin clearance rate represents the rate of radical generation in intact cells. For Northern blot analysis, total RNA was extracted using Isogen (Wako, Osaka, Japan) from the cultured cells. cDNA probes for human NOX4 encodes in the region that corresponds to amino acids 324–491, and for human p22phox encodes full length.
All values shown are expressed as means ± SEM. Statistical analysis was done by ANOVA followed by Fisher's comparison test. A p value of 0.05 or less was considered statistically significant.
mRNA Expression of NOX4 and p22phox in rat kidney
Immunostaining analysis of NOX4 and p22phox in rat kidney
Immunostaining analysis of 8-OHdG
Interventive insulin treatment
Effect of high glucose concentration on mRNA expression of NOX4 and p22phox in mesangial cells
An increased production of reactive oxygen species (ROS) is thought to contribute to the development of diabetic vascular complications [1, 2, 3, 4, 5, 6]. Since the kidney is a susceptible organ to oxidative damage [22, 23], oxidative stress could play a role in the development of diabetic nephropathy as in other diabetic vascular complications. However, the source of ROS production is not fully understood. In blood vessels, attention was recently focused on NAD(P)H oxidase as the most important source of ROS [9, 10, 11, 12]. In addition, compelling evidence has accumulated to support a role for NAD(P)H oxidase in the pathophysiology of vascular diseases including hypercholesterolaemia , atherosclerosis [14, 15, 16], and hypertension . In the kidney, NOX4 has recently been cloned as a homolog of gp91phox, the catalytic subunit of NAD(P)H oxidase [25, 26]. NOX4 protein exhibited 39% identity to gp91phox with several conservation in membrane-spanning regions and binding sites for heme, FAD, and NAD(P)H, indicative of its function as a superoxide-producing NAD(P)H oxidase. Indeed, overexpression of NOX4 in culture cells lead to increased superoxide production . It is therefore implicated that NOX4, as a major source of ROS, could play a crucial role under pathological conditions. This study showed that mRNA levels of both NOX4 and p22phox were increased in the kidney of streptozotocin-induced diabetic rats at 4 and 8 weeks after onset of diabetes determined by Northern blot analysis. These increases at 8 weeks were completely normalized by interventive insulin treatment between 6 and 8 weeks after the onset of diabetes. This result clearly confirmed that these increases were caused by the diabetic state and not by a direct toxic effect of streptozotocin. Furthermore, by immunostaining analysis of NOX4 and p22phox, several important findings were obtained. Firstly, both NOX4 and p22phox were highly expressed in distal tubular cells and to a lesser extent expressed in glomeruli. Similar localization of NOX4 and p22phox is in agreement with the idea that gp91phox and p22phox stabilize each other . Secondly, the expression levels of NOX4 and p22phox were apparently increased in both distal tubular cells and glomeruli from diabetic rats as compared with those from control rats, which was in agreement with the results of the Northern blot analysis. These data suggested that NOX4 and p22phox proteins were increased in the diabetic kidney at the transcription level. Lastly, immunostaining analysis of 8-OHdG, which is a marker of ROS-induced DNA damage, showed that the localization and levels of 8-OHdG were quite in parallel with those of NOX4 and p22phox protein expression. The 8-OHdG stains were apparently increased in both distal tubular cells and glomeruli from diabetic rats as compared with those from control rats. In addition, insulin treatment between 6 and 8 weeks after onset of diabetes completely restored the increased expression levels of NOX4 and p22phox to control levels in parallel with those of 8-OHdG. These findings strongly support the idea that NOX4 and p22phox-produced superoxide and its derivative ROS could lead to renal tissue damage in diabetic rats. In contrast, as for intracellular localization of 8-OHdG, its stains were mainly increased in the cytosol and to a lesser extent increased in the nucleus in the renal tissues of diabetic rats. This finding suggests that ROS might damage mitochondrial DNA (mtDNA) predominantly, which is in agreement with our previous report showing that 8-OHdG levels were increased in mtDNA rather than nuclear DNA in the diabetic kidney . This seems to favour the role of mitochondria as a main source of ROS rather than NAD(P)H oxidase because phagocytic NAD(P)H oxidase, by utilizing intracellular NADPH or NADH, transfers electrons across the membrane to extracellular oxygen to produce superoxide extracellularly. However, in vascular cells, it has been suggested that NAD(P)H oxidase-dependent superoxide and its derivative ROS could be produced not only extracellularly but also intracellularly [10, 18, 28]. In addition, it is also possible that long-lived ROS such as hydrogen peroxide are membrane permeable and would diffuse into the cells and inside mitochondria even if they are produced extracellularly. The predominant damage of mtDNA could be ascribed to the fact that mtDNA is vulnerable to oxidative damage due to the lack of histone and because the repair system of mtDNA is less active than that of nuclear DNA .
Several reports have shown that the activity of NAD(P)H oxidase, in parallel with the levels of its subunit protein (p22phox, p47phox or p67phox), are increased in the aorta from animal models of diabetes [19, 20] and in the saphenous vein and internal mammary artery of diabetic patients with coronary artery disease . Taken together, these results suggest that NAD(P)H oxidase might play a crucial role in the development of diabetic vascular complications including nephropathy. However, the regulation mechanism of vascular NAD(P)H oxidase is still uncertain . Previously, we showed that a high glucose concentration, a key manifestation of diabetes, could stimulate ROS production through protein kinase C (PKC)-dependent activation of NAD(P)H oxidase in cultured aortic endothelial cells and smooth muscle cells . In this study, this finding was confirmed in cultured mesangial cells exposed to a high glucose concentration for 3 days. Our study also showed that at a longer time point (7th or 9th day), a high glucose concentration induced increases in both levels of NOX4 and p22phox mRNA expression, which were also completely reversed by the co-treatment with PKC inhibitor for the last 2 days. Taken together, the results suggest that high glucose concentration induced increased expression of NAD(P)H oxidase components as well as activation of this enzyme through a PKC-dependent mechanism. However, it should not be ruled out that increased expression of NAD(P)H oxidase components might be induced secondarily as a result of persistent activation of this enzyme. It is well established that the diabetic state as well as a high glucose concentration induce PKC activation in vascular tissues including renal tissues [30, 31, 32] and the involvement of PKC in diabetes-induced renal dysfunction has been shown in animal models . PKC activation might be associated with the increased expression of NOX4 and p22phox in the diabetic kidney.
In conclusion, this study provides evidence that NAD(P)H oxidase subunits, NOX4 and p22phox, were increased in the kidney of the diabetic rat. NAD(P)H-dependent overproduction of ROS might contribute to the development of diabetic nephropathy. Thus, NAD(P)H oxidase might be a new therapeutic target for preventing the development of diabetic nephropathy.
This work was supported by a Grant-in-Aid for Scientific Research (no. 11671126) from the Ministry of Education, Science and Culture, Japan, and was supported, in part, by the Takeda Medical Fund. This work was partly carried out at Kyushu University Station for Collaborative Research.